GW 766994
Based on 2 publication(s) in Google Scholar
GW 766994 (GW 994) is an orally active and specific chemokine receptor-3 (CCR3) antagonist. GW 766994 has the potential for asthma and eosinophilic bronchitis research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.73%
- CAS. Nr.: 408303-43-5
- Formel: C21H24Cl2N4O3
- Molecular Weight:451.35
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) GW 766994
More
Biologische Aktivität
|
CCR3 7.86 (pKi) |
GW 766994 is a specific chemokine receptor-3 (CCR3) antagonist, which has entered clinical trial for asthma and eosinophilic bronchitis[1]. GW 766994 (10 μM) reverses CCL11-induced activation of CDK5, phosphorylations of CDK5, GSK3β, and increased phosphorylation of tau in hippocampal neurons[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 408303-43-5
-
Appearance Solid
-
Molecular Weight 451.35
-
Formel C21H24Cl2N4O3
-
Color Light yellow to yellow
-
SMILES
NC(C(C=C1)=CC=C1CNC(NC[C@H](OCC2)CN2CC3=CC(Cl)=C(Cl)C=C3)=O)=O
-
Synonyms
GW 994
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Nat Cancer
Autotaxin-lysolipid signaling suppresses a CCL11-eosinophil axis to promote pancreatic cancer progression. [Abstract]2024 Feb;5(2):283-298. PMID: 38195933 -
Cell Mol Immunol
CCL5 deficiency promotes liver repair by improving inflammation resolution and liver regeneration through M2 macrophage polarization. [Abstract]2020 Jul;17(7):753-764. PMID: 31481754
Lösungsmittel & Löslichkeit
DMSO : 56 mg/mL (124.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.33 mg/mL (5.16 mM); Clear solution
This protocol yields a clear solution of ≥ 2.33 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (23.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.33 mg/mL (5.16 mM); Clear solution
This protocol yields a clear solution of ≥ 2.33 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (23.3 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (271 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Neighbour H, et al. Safety and efficacy of an oral CCR3 antagonist in patients with asthma and eosinophilic bronchitis: a randomized, placebo-controlled clinical trial. Clin Exp Allergy. 2014 Apr;44(4):508-16. [Content Brief]
[2]. Zhu C, et al. Targeting CCR3 to Reduce Amyloid-β Production, Tau Hyperphosphorylation, and Synaptic Loss in a Mouse Model of Alzheimer's Disease. Mol Neurobiol. 2017 Dec;54(10):7964-7978. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2156 mL | 11.0779 mL | 22.1558 mL | 55.3894 mL |
| 5 mM | 0.4431 mL | 2.2156 mL | 4.4312 mL | 11.0779 mL | |
| 10 mM | 0.2216 mL | 1.1078 mL | 2.2156 mL | 5.5389 mL | |
| 15 mM | 0.1477 mL | 0.7385 mL | 1.4771 mL | 3.6926 mL | |
| 20 mM | 0.1108 mL | 0.5539 mL | 1.1078 mL | 2.7695 mL | |
| 25 mM | 0.0886 mL | 0.4431 mL | 0.8862 mL | 2.2156 mL | |
| 30 mM | 0.0739 mL | 0.3693 mL | 0.7385 mL | 1.8463 mL | |
| 40 mM | 0.0554 mL | 0.2769 mL | 0.5539 mL | 1.3847 mL | |
| 50 mM | 0.0443 mL | 0.2216 mL | 0.4431 mL | 1.1078 mL | |
| 60 mM | 0.0369 mL | 0.1846 mL | 0.3693 mL | 0.9232 mL | |
| 80 mM | 0.0277 mL | 0.1385 mL | 0.2769 mL | 0.6924 mL | |
| 100 mM | 0.0222 mL | 0.1108 mL | 0.2216 mL | 0.5539 mL |